Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) (HOPE-PROSTATE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05885009 |
|
Recruitment Status :
Recruiting
First Posted : June 1, 2023
Last Update Posted : June 1, 2023
|
Sponsor:
SOLTI Breast Cancer Research Group
Collaborators:
Pfizer
AstraZeneca
Merck Sharp & Dohme LLC
Advanced Accelerator Applications
Astellas Pharma Inc
Guardant Health, Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 28, 2026 |
| Estimated Study Completion Date : | March 28, 2028 |